Acute myeloid leukemia cells in G0 phase of the cell cycle that are unresponsive to conventional chemotherapy are sensitive to treatment with granulocyte-macrophage colony-stimulating factor/diphtheria toxin fusion proteins

Experimental Hematology

Volumn 32, Issue 2, 2004, Pages 188-194

  Jedema, Inge ^a   Barge, Renée M Y ^a   Frankel, Arthur E ^b   Willemze, Roel ^a   Falkenburg, J H Frederik ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIPHTHERIA TOXIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CELL CYCLE; CELL DEATH; CELL KILLING; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; HUMAN; HUMAN CELL; LEUKEMIA CELL; PRIORITY JOURNAL; TARGET CELL;

EID: 0842287498     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exphem.2003.11.005     Document Type: Article

References (26)

1. Zittoun R.A., Mandelli F., Willemze R., et al. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Leukemia Cooperative Groups. N Engl J Med. 332:1995;217-223.
2. Lowenberg B., Downing J.R., Burnett A. Acute myeloid leukemia. N Engl J Med. 341:1999;1051-1062.
3. List A.F. Role of multidrug resistance and its pharmacological modulation in acute myeloid leukemia. Leukemia. 10:1996;937-942.
4. Pirker R., Wallner J., Geissler K., et al. MDR1 gene expression and treatment outcome in acute myeloid leukemia. J Natl Cancer Inst. 83:1991;708-712.
5. Stoetzer O.J., Nussler V., Darsow M., et al. Association of bcl-2, bax, bcl-xL and interleukin-1 beta-converting enzyme expression with initial response to chemotherapy in acute myeloid leukemia. Leukemia. 10:(suppl 3):1996;S18-S22.
6. Maung Z.T., MacLean F.R., Reid M.M., et al. The relationship between bcl-2 expression and response to chemotherapy in acute leukaemia. Br J Haematol. 88:1994;105-109.
7. Jedema I., Barge R.M., Willemze R., Falkenburg J.H. High susceptibility of human leukemic cells to Fas-induced apoptosis is restricted to G(1) phase of the cell cycle and can be increased by interferon treatment. Leukemia. 17:2003;576-584.
8. Jedema I., Barge R.M.Y., Nijmeijer B.A., Willemze R., Falkenburg J.H.F. Recruitment of leukemic cells from G0 phase of the cell cycle by interferons results in conversion of resistance to daunorubicin. Leukemia. 17:2003;2049-2051.
9. Hegewisch-Becker S. MDR1 reversal: criteria for clinical trials designed to overcome the multidrug resistance phenotype. Leukemia. 10:(suppl 3):1996;S32-S38.
10. Solary E., Witz B., Caillot D., et al. Combination of quinine as a potential reversing agent with mitoxantrone and cytarabine for the treatment of acute leukemias: a randomized multicenter study. Blood. 88:1996;1198-1205.
11. Sundman-Engberg B., Tidefelt U., Paul C. Effect of cytokines on the toxicity of cytostatic drugs on leukemic cells in vitro and in vivo. Eur J Haematol. 56:1996;1-6.
12. Estey E., Thall P., Andreeff M., et al. Use of granulocyte colony-stimulating factor before, during, and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: comparison with fludarabine plus cytarabine without granulocyte colony-stimulating factor. J Clin Oncol. 12:1994;671-678.
13. Perentesis J.P., Waddick K.G., Bendel A.E., et al. Induction of apoptosis in multidrug-resistant and radiation-resistant acute myeloid leukemia cells by a recombinant fusion toxin directed against the human granulocyte macrophage colony-stimulating factor receptor. Clin Cancer Res. 3:1997;347-355.
14. Frankel A.E., Hall P.D., McLain C., et al. Cell-specific modulation of drug resistance in acute myeloid leukemic blasts by diphtheria fusion toxin, DT388-GMCSF. Bioconjug Chem. 9:1998;490-496.
15. Frankel A.E., Ramage J., Latimer A., et al. High-level expression and purification of the recombinant diphtheria fusion toxin DTGM for PHASE I clinical trials. Protein Exp Purif. 16:1999;190-201.
16. Budel L.M., Touw I.P., Delwel R., Clark S.C., Lowenberg B. Interleukin-3 and granulocyte-monocyte colony-stimulating factor receptors on human acute myelocytic leukemia cells and relationship to the proliferative response. Blood. 74:1989;565-571.
17. Kurata H., Arai T., Yokota T., Arai K. Differential expression of granulocyte-macrophage colony-stimulating factor and IL-3 receptor subunits on human CD34+ cells and leukemic cell lines. J Allergy Clin Immunol. 96:1995;1083-1099.
18. Stanley E., Lieschke G.J., Grail D., et al. Granulocyte/macrophage colony-stimulating factor-deficient mice show no major perturbation of hematopoiesis but develop a characteristic pulmonary pathology. Proc Natl Acad Sci USA. 91:1994;5592-5596.
19. Wognum A.W., Westerman Y., Visser T.P., Wagemaker G. Distribution of receptors for granulocyte-macrophage colony-stimulating factor on immature CD34+ bone marrow cells, differentiating monomyeloid progenitors, and mature blood cell subsets. Blood. 84:1994;764-774.
20. Terpstra W., Rozemuller H., Breems D.A., et al. Diphtheria toxin fused to granulocyte-macrophage colony-stimulating factor eliminates acute myeloid leukemia cells with the potential to initiate leukemia in immunodeficient mice, but spares normal hemopoietic stem cells. Blood. 90:1997;3735-3742.
21. Frankel A.E., Hall P.D., Burbage C., et al. Modulation of the apoptotic response of human myeloid leukemia cells to a diphtheria toxin granulocyte-macrophage colony-stimulating factor fusion protein. Blood. 90:1997;3654-3661.
22. Frankel A.E., Powell B.L., Hall P.D., Case L.D., Kreitman R.J. Phase I trial of a novel diphtheria toxin/granulocyte macrophage colony-stimulating factor fusion protein (DT388GMCSF) for refractory or relapsed acute myeloid leukemia. Clin Cancer Res. 8:2002;1004-1013.
23. Lange B., Valtieri M., Santoli D., et al. Growth factor requirements of childhood acute leukemia: establishment of GM-CSF-dependent cell lines. Blood. 70:1987;192-199.
24. Sievers E.L. Clinical studies of new "biologic" approaches to therapy of acute myeloid leukemia with monoclonal antibodies and immunoconjugates. Curr Opin Oncol. 12:2000;30-35.
25. Hogge D.E., Willman C.L., Kreitman R.J., et al. Malignant progenitors from patients with acute myelogenous leukemia are sensitive to a diphtheria toxin-granulocyte-macrophage colony-stimulating factor fusion protein. Blood. 92:1998;589-595.
26. Kim C.N., Bhalla K., Kreitman R.J., et al. Diphtheria toxin fused to granulocyte-macrophage colony-stimulating factor and Ara-C exert synergistic toxicity against human AML HL-60 cells. Leuk Res. 23:1999;527-538.